Back

Clinical and Histological Outcomes of Patients with Barrett’s Esophagus Undergoing Endoscopic Submucosal Dissection

Clinical and Histological Outcomes of Patients with Barrett's Esophagus Undergoing Endoscopic Submucosal Dissection

  • Clinical Trial Information

    Trial Contact: Garcia de Djuro, Ginette; Britton, David ; Shepherd, Adriane R

  • IRB No: 22.128.06

    Protocol Abbrev: Clinical & Histological Outcomes (ESD)

    Principal Investigator: Ji Young Bang, MD

    Age Group: Adult

  • Objective

    Aim 1: To measure the rates and predictors of CRIM (Complete Remission of Intestinal Metaplasia) and CRD (Complete Remission of Dysplasia) following treatment of dysplasia in Barrett’s esophagus
    Aim 2: To measure the safety profile of ESD in the treatment of patients with Barrett’s esophagus/neoplasia.
    Aim 3: To measure the recurrence rate of dysplastic Barrett’s esophagus and esophageal adenocarcinoma (EAC) after achieving CRD and CRIM at all three Mayo Clinic campuses, and non-Mayo academic centers including Cleveland Clinic, University Hospitals Cleveland, and Orlando Health
    Aim 4: To identify the predictors of recurrent intestinal metaplasia (with and without dysplasia or EAC) in patients with dysplastic Barrett’s esophagus and early-stage EAC who had achieved CRD and CRIM with endoscopic eradication therapy comprised of ESD followed by ablation.

  • Key Eligibility

    Retrospective and prospective data collection; outcomes.